Merck & Co. has voluntarily recalled VAQTA (Hepatitis A vaccine, Inactivated) in prefilled syringes after tests revealed a decreased antigen content in some syringes that was below the established minimum specification. As a result, some patients who were vaccinated with the affected lots may be insufficiently protected from hepatitis A.
Vaccine claims are very complex, and must be made under the National Vaccine Injury Compensation program, which is administered by the United States Court of Federal Claims in Washington, D.C.